BioOhio remembers Frank Samuel, President of VentureOhio

Posted by BioOhio on Oct. 21, 2014

Frank Samuel PICAll of us at BioOhio are saddened to share the news that Frank Samuel, President of VentureOhio, was killed yesterday afternoon in a single car accident in Northeast Ohio. Frank was one of Ohio’s most vibrant leaders, including serving as BioOhio’s second President.

“Frank was a good man and a good friend to many, and he will be sorely missed,” said John Rice, Managing Partner at Triathlon Medical Ventures & BioOhio Board Member, “Please keep him, his wife Jacqueline and his family in your thoughts and prayers.”

BioOhio was fortunate to have Frank join us just weeks ago as a speaker at our Annual Conference in Cincinnati. He spoke with great passion about his newest endeavor, VentureOhio. Frank highlighted the need to build infrastructure around the investment community to support entrepreneurial efforts in Ohio.

“I am often asked, why create VentureOhio? Because the time had come. We need three things to succeed; capital managed in Ohio, from early stage through maturity; a robust ecosystem to support entrepreneurship; and effective storytelling about all the successes that happen in Ohio.”

A press release from VentureOhio will be released soon, and articles in Cleveland and around the state will also appear. More information is available here.

Our thoughts and sympathies go out to his family and everyone that knew him.

Frank Samuel was President of VentureOhio, Inc. an organization founded in 2013 to advance entrepreneurial business growth in Ohio. Prior to this position, he was founding President of the Geauga Growth Partnership, Inc., a business-led economic development organization in Geauga County (Northeast Ohio). He was Science and Technology Advisor to the Governor of Ohio from 2000 – 2007, when he was a principal architect of Ohio’s Third Frontier program. Frank worked to advance Ohio’s bioscience community as BioOhio’s second President. Samuel served on the National Advisory Council of the California Health Benefits Review Program and the Board of Directors of the Global Cardiology Innovation Center of the Cleveland Clinic. He served as Chair and Board member for Providence Hospital (Washington, D.C.), a member of Institute of Medicine advisory bodies on biomedical technology issues, a member of several biomedical company boards of directors, and President of the Health Industry Manufacturers Association (now AdvaMed).  A graduate of Hiram College and Harvard Law School, his paper recommending a venture capital strategy for the Great Lakes region was published in 2010 by The Brookings Institution (Washington, D.C.).

Two great events in Northeast Ohio!

Posted by BioOhio on Oct. 10, 2014

BioOhio is excited to host two events in Northern Ohio this Thursday! We hope to see everyone from the bioscience community represented at one or both of these excellent functions on October 16th!

BioOhio Annual Conference Road Show

BioOhio Regulatory Forum

The Annual Conference focuses on innovation and growth in Ohio’s bioscience community, and the Regulatory Forum features presentations by FDA and industry experts, as well as panel discussions for you to ask the experts your unanswered regulatory questions.

Both events offer content from dynamic speakers, excellent networking, and will bring Ohio’s bioscience community together to explore new opportunities and discoveries in research, innovation, tech licensing, financing, business development, partnerships, workforce & education, regulatory, advocacy and membership benefits.

The location is The Bertram Inn & Conference Center in Aurora. This beautiful venue will allow you to escape from routine surroundings for a day and focus on the root of your bioscience pathway, career, goals and challenges.

Visit the event pages on our website to view agenda and registration details: Annual Conference / Regulatory Forum


Higher Risk, Higher Reward Innovations are the Future

Posted by BioOhio on Oct. 06, 2014

AC2014-Andrew-CothrelBioOhio is glad to introduce a new contributor to micrOHscope, Andrew Cothrel, CEO of BioOhio member company NovoSource. Andrew has had a long career as a medtech/biotech executive, advisor, and consultant, covering diagnostics & patient monitoring, life science research tools, and medical devices including orthopedics, cardiovascular, and surgical tools.

Thanks again to BioOhio for inviting me to be part of its September 18th conference. I wanted to provide some follow-up to my comments during the panel discussion on innovation, because I received a number of questions after the panel adjourned that we ran out of time to answer.

In the panel, I spoke of how innovation is changing, and opportunities are moving in the venture model from reimbursement-driven incremental product innovation to business model innovation and step-change product innovation. To illustrate, I used some examples from orthopedics, although the comments apply to many other fields as well.

To clarify, I am definitely not saying that incremental innovation in orthopedics, even in areas as staid as total knees and total hips, is dead – far from it. What I wanted to communicate is that incremental innovation – whether it is an improved coating that better promotes bony ingrowth, or a design feature that makes future revisions easier, or whatever it may be – is no longer the province of the venture model. Those types of innovations will come exclusively from the large, established players, because the amount of clinical improvement those incremental innovations create does not justify the costs and risks (relative to the reward) associated with pursuing them in a venture model.

Where the venture model will turn (has turned) in orthopedics is to the higher risk, higher reward innovations that have the potential to make step-change improvements in patient outcomes. Whether it is in biologics, nano-materials, or other areas of innovation, this is the future of the venture model in orthopedics. To be blunt, the days of cranking up yet another set of (more or less functionally equivalent) designs for a spine product line (or knee, or hip…), pretending that is product innovation, and raising private capital around it are over.

What is really ripe for innovation is the non-product side of the orthopedic business. Risk sharing, pricing models, asset ownership, “repless” models, servicing of instruments, and more are beginning to experience disruptive approaches that can come from either venture-backed models or existing industry players. We are seeing signs that this is increasingly being recognized in the industry, and being part of this change as it plays out will be an exciting journey.

I hope that helps to address many of the questions I did not have time to address on the 18th. If anyone has additional questions on this topic, I can be contacted at or

And while I’m at it, I hope to see everyone at BioOhio’s Central Ohio Annual Conference Road Show on November 12th. I’ll be on a panel for a different topic this time – focusing on successful business strategies, including David Blauer of Bjond Health, Joseph Gardner of Aerpio Therapeutics and Neill Lane of Stirling Ultracold.

BIO Washington Update, October 2014

Posted by BioOhio on Oct. 06, 2014

CSBA BIO and Republic Consulting

October 6, 2014

Legislators worked efficiently to address key legislation in September before adjourning for the mid-term elections. Congress approved a continuing resolution (CR) to extend federal funding of government agencies through December 11, 2014. Both the Administration and Congress moved forward on some tax and transportation issues, while continuing to defer action on the expired tax extenders and a possible executive order on immigration. Much of the month was defined by events transpiring outside of the U.S., including the deteriorating situation in Iraq and Syria and the Ebola outbreak in Western Africa. Many of these issues will require additional consideration when Congress returns in November for the Lame Duck session.


With the clock ticking down, Congress agreed to extend funding for the federal government at existing funding levels before leaving for election season. The government had been operating on funding from a previous CR that was set to expire at the end of Fiscal Year 2014 (FY14) on September 30, 2014. The new CR will fund the government through December 11, 2014.


BioOhio member NanoLogix making news at home and abroad

Posted by BioOhio on Sep. 30, 2014

Nanologix-200NanoLogix announced yesterday that UNITAID, based in Geneva, Switzerland and hosted by the World Health Organization, recently published their Tuberculosis Diagnostics Technology and Market Landscape – 3rd Edition. NanoLogix’s sandwiched membrane BNP rapid testing technology for tuberculosis is cited on pages 17 and 37, marking the second year it has been mentioned in the UNITAID report.

More good news from NanoLogix features a member-to-member connection as The Ohio State University joins the growing list of educational institutions ordering NanoLogix products. These include the University of Colorado-Boulder, Massachusetts Institute of Technology, Worcester Polytechnic Institute, and Cardiff University of Wales, UK. In addition, NanoLogix has sold product to Abbott Labs, personal care companies, food processing companies, soil testing companies, the US EPA, and others.

We are always excited to see bioscience companies in Ohio getting such great traction in the global market. Stay tuned for more news from NanoLogix!

Read the full press release here (pdf). Read the UNITAID report here.

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog


BioOhio Member Mark BioOhio Member

NanoLogix developing rapid test for Ebola virus (video) | WYTV33 Youngstown, October 21, 2014

Analytic, a partnership of Anatrace and Microlytic: enabling membrane protein research | PR Web, October 21, 2014

Quasar Energy Group uses organic waste to produce renewable energy | Todays Energy Solutions, October 21, 2014

Frank Samuel, President of VentureOhio and former BioOhio President dies in auto accident | Geauga County Maple Leaf, October 21, 2014

Milo Biotechnology’s follistatin gene therapy increases function in Becker Muscular Dystrophy patients | PR Newswire, October 20, 2014

OSU Wexner Medical Center study: new implantable device to control heart failure shows promising results | Todays Medical Developments, October 17, 2014

Assurex Health gets $6M funding for clinical trial related to patients with depression or schizophrenia | Cincinnati Business Courier, October 17, 2014

University of Cincinnati lands grant to attack hepatitis C among needle users in 20 counties | WCPO9 Cincinnati, October 16, 2014

Control Bionics interview, developing technology that enables individuals with debilitating conditions to communicate | The Clermont Sun, October 16, 2014

BioOhio member Oralectrics spinout Zumby opens crowdfunding campaign |, October 16, 2014

Ohio State sophomore Peeyush Shrivastava of Genetesis named a finalist in $5M 43North business plan competition | Columbus Business First, October 16, 2014

Navidea hires Rick Gonzalez as CEO from Spectrum Pharmaceuticals, replaces Michael Goldberg, Navidea’s lead investor | Columbus Business First, October 15, 2014

Health Care DataWorks’ Chief Data Scientist to present at healthcare conference sponsored by HIMSS Georgia Chapter | PR Web, October 15, 2014

FDA approves expanded use of Navidea’s Lymphoseek for lymphatic mapping in solid tumors | Business Wire, October 15, 2014

Crowdfunding launches today for Animal Oralectrics’ new medical device for dogs that fights oral bacteria while playing | PR Newswire, October 15, 2014

NanoLogix technology being configured for rapid Ebola and Enterovirus detection | Business Wire, October 14, 2014

Nanotronics Imaging releases nSPEC 3D, powerful microscope that captures 3D images at nanoscale, in lightning speed | Business Wire, October 14, 2014

Cincinnati Children’s Hospital Medical Center announces a new treatment designed to save more eyes from cancer | PR Newswire, October 14, 2014

Ischemia Care raises $1.9M for stroke detection technology | MedCity News, October 13, 2014

STERIS to acquire Synergy Health for $1.9 Billion in cash and stock | STERIS, October 13, 2014